ALT5 Sigma (ALTS) Competitors $3.06 -0.36 (-10.53%) Closing price 04:00 PM EasternExtended Trading$3.06 0.00 (0.00%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. MNPR, DSGN, CGC, CTMX, LRMR, MBX, IMRX, FDMT, ALT, and TVRDShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Monopar Therapeutics (MNPR), Design Therapeutics (DSGN), Canopy Growth (CGC), CytomX Therapeutics (CTMX), Larimar Therapeutics (LRMR), MBX Biosciences (MBX), Immuneering (IMRX), 4D Molecular Therapeutics (FDMT), Altimmune (ALT), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors Monopar Therapeutics Design Therapeutics Canopy Growth CytomX Therapeutics Larimar Therapeutics MBX Biosciences Immuneering 4D Molecular Therapeutics Altimmune Tvardi Therapeutics ALT5 Sigma (NASDAQ:ALTS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do insiders & institutionals have more ownership in ALTS or MNPR? 6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ALTS or MNPR more profitable? Monopar Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Monopar Therapeutics' return on equity of -41.76% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-74.89% -179.27% -16.28% Monopar Therapeutics N/A -41.76%-39.49% Do analysts recommend ALTS or MNPR? Monopar Therapeutics has a consensus price target of $82.33, suggesting a potential upside of 6.32%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, ALTS or MNPR? ALT5 Sigma has higher revenue and earnings than Monopar Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$12.53M5.28-$6.24MN/AN/AMonopar TherapeuticsN/AN/A-$15.59M-$3.33-23.26 Which has more risk and volatility, ALTS or MNPR? ALT5 Sigma has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Does the media refer more to ALTS or MNPR? In the previous week, Monopar Therapeutics had 14 more articles in the media than ALT5 Sigma. MarketBeat recorded 15 mentions for Monopar Therapeutics and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 1.91 beat Monopar Therapeutics' score of 0.78 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Overall Sentiment ALT5 Sigma Very Positive Monopar Therapeutics Positive SummaryMonopar Therapeutics beats ALT5 Sigma on 8 of the 14 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$66.13M$7.84B$12.57B$10.30BDividend YieldN/A4.74%5.44%4.62%P/E RatioN/A17.04239.0626.11Price / Sales5.287.2331.67171.57Price / CashN/A27.6922.7761.52Price / Book6.242.962.276.30Net Income-$6.24M$313.53M$1.01B$271.03M7 Day Performance-16.85%-1.00%-1.16%-0.14%1 Month Performance-55.00%7.56%1.15%6.42%1 Year Performance72.88%28.18%540.31%28.81% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.3067 of 5 stars$3.06-10.5%N/A+81.4%$66.13M$12.53M0.00170Positive NewsGap DownHigh Trading VolumeMNPRMonopar Therapeutics2.0346 of 5 stars$57.00+4.6%$71.75+25.9%+1,556.2%$336.20MN/A-17.1210News CoverageAnalyst ForecastGap UpDSGNDesign Therapeutics0.2633 of 5 stars$5.85-0.2%N/A+19.0%$333.72MN/A-5.2240Positive NewsCGCCanopy Growth1.0181 of 5 stars$1.45+4.3%N/A-69.1%$333.39M$225.65M-0.483,150Positive NewsGap DownCTMXCytomX Therapeutics4.1972 of 5 stars$1.96-1.5%$5.75+193.4%+102.5%$328.18M$138.10M3.50170Analyst ForecastAnalyst RevisionGap DownLRMRLarimar Therapeutics2.4122 of 5 stars$4.00+1.0%$18.43+360.7%-20.4%$327.80MN/A-2.5630Positive NewsMBXMBX Biosciences2.8835 of 5 stars$9.74-10.4%$37.63+286.3%-12.6%$327.21MN/A-2.1536Trending NewsAnalyst ForecastGap DownIMRXImmuneering3.5094 of 5 stars$8.31+5.7%$13.75+65.5%+216.1%$326.74M$320K-4.4060Trending NewsAnalyst ForecastGap UpFDMT4D Molecular Therapeutics2.7692 of 5 stars$6.69-1.6%$30.40+354.4%-26.5%$317.58M$40K-1.90120Positive NewsALTAltimmune2.6765 of 5 stars$3.63+1.1%$17.40+379.3%-44.9%$316.84M$20K-3.0850TVRDTvardi Therapeutics1.7243 of 5 stars$33.83+0.2%$64.25+89.9%N/A$316.58M$7.14M0.0080Positive News Related Companies and Tools Related Companies MNPR Alternatives DSGN Alternatives CGC Alternatives CTMX Alternatives LRMR Alternatives MBX Alternatives IMRX Alternatives FDMT Alternatives ALT Alternatives TVRD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALTS Stock Alerts